5.235USD-2.88%Mkt Cap: 339.34M USDP/E: —Last update: 2026-05-26
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a P…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap339.34M USD
Enterprise Value184.76M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-56.02M USD
Revenue/Share—
Last Price5.235 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees53
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.90
PEG—
EV/EBITDA-3.14
EV/Revenue—
P/S—
P/B1.54
EPS (TTM)-1.06
EPS (Forward)-1.34
52W Range
1.42044% of range10.08
52W High10.08 USD
52W Low1.420 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-25.64%
ROA-24.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.34M USD
CapEx (TTM)142.23K USD
FCF Margin—
FCF Yield-9.77%
Net Debt-152.96M USD
Net Debt/EBITDA2.60
Balance Sheet
Debt/Equity0.02
Current Ratio32.45
Quick Ratio31.50
Book Value/Sh3.380 USD
Cash/Share2.422 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)17.00 USD
Target Range11.00 USD – 30.00 USD
# Analysts6
Ownership
Shares Out.64.70M
Float49.44M
Insiders17.81%
Institutions47.17%
Short Interest
Short Ratio12.4d
Short % Float19.35%
Short % Out.14.68%
Shares Short9.50M
Short (prev mo.)10.30M
Technical
SMA 505.308 (-1.4%)
SMA 2005.761 (-9.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.13M
Avg Vol (10d)698.45K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—